Grace M. Alexandrow

Grace M. Alexandrow

Auto-generated profile, based on publicly available information

Grace M. Alexandrow

Department of Pharmacology & Therapeutics, University of Florida, Gainesville, Florida

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
New agents are needed that selectively kill cancer cells without harming normal tissues. The TRAIL ligand and its receptors, DR5 and DR4, exhibit cancer-selective toxicity. TRAIL analogs or agonistic antibodies targeting these receptors are available but have not yet received FDA approval for cancer therapy. Small molecules for activating DR5 or DR4 independently of protein ligands may activate TRAIL receptors as a monotherapy or potentiate the efficacy of TRAIL analogs and agonistic antibodies. Previously described disulfide bond–disrupting agents activate DR5 by altering its disulfide bonding through inhibition of protein disulfide isomerases ERp44, AGR2, and PDIA1. Work presented in this article extends these findings by showing that disruption of single DR5 disulfide bonds causes high-level DR5 expression, disulfide-mediated clustering, and activation of caspase 8/caspase 3–mediated proapoptotic signaling. Recognition of the extracellular domain of DR5 by various antibodies is strongly influenced by the pattern of DR5 disulfide bonding, which has important implications for the use of agonistic DR5 antibodies for cancer therapy and as research tools. Importantly, other endoplasmic reticulum (ER) stressors, including thapsigargin and tunicamycin, also alter DR5 disulfide bonding in various cancer cell lines, and in some instances, DR5 mis-disulfide bonding is potentiated by overriding the integrated stress response (ISR) with inhibitors of the PERK kinase or the ISR inhibitor ISRIB. These observations indicate that the pattern of DR5 disulfide bonding functions as a sensor of ER stress and serves as an effector of proteotoxic stress by driving extrinsic apoptosis independently of extracellular ligands. Implications: Extreme ER stress triggers triage of transmembrane receptor production, whereby mitogenic receptors are downregulated and death receptors are simultaneously elevated.

2 July 2025
Verified
Other
Open access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
Supplementary Figure S2. Neither CDCP1 overexpression, or inhibition of eEF2 kinase influence DDA induction of DR5 upregulation, DR4/5 oligomerization, or Caspase 8 cleavage.

2 July 2025
Verified
Other
Open access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
Supplementary Figure S1. DDAs upregulate DR5 and TNFR1 with minimal effect on other Death Receptors tested. Immunoblot analysis of the indicated cell lines treated for 24 h with the specified dMtcyDTDO concentrations and analyzed by immunoblot under non-reducing conditions.

2 July 2025
Verified
Other
Open access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
New agents are needed that selectively kill cancer cells without harming normal tissues. The TRAIL ligand and its receptors, DR5 and DR4, exhibit cancer-selective toxicity. TRAIL analogs or agonistic antibodies targeting these receptors are available but have not yet received FDA approval for cancer therapy. Small molecules for activating DR5 or DR4 independently of protein ligands may activate TRAIL receptors as a monotherapy or potentiate the efficacy of TRAIL analogs and agonistic antibodies. Previously described disulfide bond–disrupting agents activate DR5 by altering its disulfide bonding through inhibition of protein disulfide isomerases ERp44, AGR2, and PDIA1. Work presented in this article extends these findings by showing that disruption of single DR5 disulfide bonds causes high-level DR5 expression, disulfide-mediated clustering, and activation of caspase 8/caspase 3–mediated proapoptotic signaling. Recognition of the extracellular domain of DR5 by various antibodies is strongly influenced by the pattern of DR5 disulfide bonding, which has important implications for the use of agonistic DR5 antibodies for cancer therapy and as research tools. Importantly, other endoplasmic reticulum (ER) stressors, including thapsigargin and tunicamycin, also alter DR5 disulfide bonding in various cancer cell lines, and in some instances, DR5 mis-disulfide bonding is potentiated by overriding the integrated stress response (ISR) with inhibitors of the PERK kinase or the ISR inhibitor ISRIB. These observations indicate that the pattern of DR5 disulfide bonding functions as a sensor of ER stress and serves as an effector of proteotoxic stress by driving extrinsic apoptosis independently of extracellular ligands.Implications:Extreme ER stress triggers triage of transmembrane receptor production, whereby mitogenic receptors are downregulated and death receptors are simultaneously elevated.

2 July 2025
Verified
Other
Open access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
Supplementary Figure S3. Neither CDCP1 overexpression, or inhibition of eEF2 kinase influence DDA induction of DR5 upregulation, DR4/5 oligomerization, or Caspase 8 cleavage.

2 July 2025
Verified
Other
Open access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
Supplementary Table 1. Mass parameters for tcyDTDO, dMtcyDTDO, dFtcyDTDO, and internal standard (IS)